A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
Study Details
Study Description
Brief Summary
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is little known. This study would recruit 400 Chinese EOC patients with known targeted gene mutations via a multi-panel testing of 27 genes, including BRCA1/BRCA2. All patients accept evaluation of HRD model, which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Epithelial ovarian cancer patients sensitive to platinum based chemotherapy
|
Genetic: Evaluation of homologous recombination deficiency score
Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
|
| Epithelial ovarian cancer patients resistant to platinum based chemotherapy
|
Genetic: Evaluation of homologous recombination deficiency score
Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
|
Outcome Measures
Primary Outcome Measures
- Homologous recombination deficiency (HRD) score [Two years]
The HRD score for individual patient is a scale describing her HRD status. The score model is calculated by the analysis for three types of important molecular mechanism: loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The minimum value is 0, but the maximun value is not available. Higher scores mean more sensitivity to poly-ADP-ribose polymerase inhibitor.
Secondary Outcome Measures
- Progression-free survival [Five years]
Progression-free survival in recruited patients
- Overall survival [Five years]
Overall survival in recruited patients
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged 18 years or older
-
Pathological confirmation of epithelial ovarian cancer
-
With available tumor tissues
-
Given consents to participate the study
Exclusion Criteria:
- Not meeting all of the inclusion criteria
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Lei Li | Beijing | Beijing | China | 100730 |
Sponsors and Collaborators
- Lei Li
Investigators
- Principal Investigator: Lei Li, M.D., Peking Union Medical College Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EOC-HRD2